A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children with Achondroplasia

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children with Achondroplasia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Vosoritide (Primary)
  • Indications Achondroplasia
  • Focus Registrational; Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 22 Feb 2018 Children in this study will have completed a minimum six-month baseline study to determine their respective baseline growth velocity prior to entering this study, as reported in a BioMarin media release.
    • 26 Oct 2017 According to BioMarin media release, company expects to complete enrollment of the Phase 3 study in mid-2018 and provide top-line data in the second half of 2019.
    • 02 Aug 2017 According to BioMarin media release, company plans to provide an update on the most recent data available with vosoritide at the upcoming R&D Day event on 18 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top